Half-Year 2022 Financial and Clinical Trials Update
Tecentriq
Anti-PD-L1 cancer immunotherapy - breast cancer
Indication
Neoadjuvant triple negative breast cancer (TNBC)
Adjuvant triple negative breast cancer (TNBC)
Phase/study
# of patients
Design
Phase III
IMpassion031
N=333
ARM A: Tecentriq plus nab-paclitaxel
ARM B: Placebo plus nab-paclitaxel
Primary endpoint
Status
■ Percentage of participants with pathologic complete response
FPI Q3 2017
Recruitment completed Q2 2018
Study met primary endpoint Q2 2020
■ Data presented at ESMO 2020
Data published in Lancet 2020;396 (10257):1090-1100
Filed in EU Q4 2020 - application withdrawn Q3 2021
CT Identifier
NCT03197935
PD-L1-Programmed cell death-ligand 1; ESMO-European Society for Medical Oncology
Phase III
IMpassion030
N=2,300
▪ ARM A: Tecentriq plus paclitaxel followed by AC followed by Tecentriq
plus AC, followed by Tecentriq maintenance
ARM B: Placebo plus paclitaxel followed by AC followed by placebo
Invasive disease-free survival
FPI Q3 2018
NCT03498716
Roche
95
OncologyView entire presentation